经皮射频毁损治疗肝恶性肿瘤患者医院感染病例对照研究

A case-control study of nosocomial infection for patients with percutaneous radiofrequency ablation of liver malignancies

目的了解经皮射频毁损(radiofrequency ablation,RFA)治疗肝恶性肿瘤患者医院感染发生情况。方法采用病例对照研究方法,回顾性调查34例RFA治疗者与同期42例接受放、化疗治疗而非RFA治疗者(对照组)发生医院感染的情况,并进行分析。结果RFA治疗组的医院感染率为8.82%,对照组为52.38%,两组比较,差异有显著性(χ2=16.14,P<0.001,OR=0.09);RFA治疗组疗效显著且副反应小。结论RFA治疗组医院感染率明显低于对照组,可能与RFA治疗后细胞免疫增强而传统的放、化疗患者细胞免疫力降低有关。

Objective To evaluate the nosocomial infection （NI） for the patients with liver malignancies treated with percutaneous radiofrequency ablation （RFA）. Methods With the method of case control study, the status of NI were analysed retrospectively for 34 patients with liver malignancies treated with RFA, and 42 patients with liver cancer treated with radiotherapy and chemotherapy but without RFA were as controls. Results The rate of NI in RFA group was 8.82 %, and the rate in non-RFA group was 52.38% （x^2 = 16.14, P 〈 0. 001, OR = 0.09）. There was significant difference between two groups. RFA was effective for the treatment of liver malignancies with little side effect. Conclusion The NI rate in RFA group was lower than that of non-RFA group. The possible reason was enhanced cellular immunity after RFA, but depressed cellular immunity after chemotherapy and radiotherapy.